Sepideh GhazaeeKateryna Marchenko-TolstaPetro SeredaSandra Lane2024-10-292024-10-292023-09-12Ghazaee , S., Marchenko-Tolsta , K., Sereda , P., & Lane , S. (2023). RENOPROTECTIVE PROPERTIES OF NOVEL ANTI-DIABETIC AGENTS. Collection of Scientific Papers «SCIENTIA», (August 25, 2023; Zagreb, Croatia), 214–215. Retrieved from https://previous.scientia.report/index.php/archive/article/view/1174979-8-88955-770-8https://previous.scientia.report/index.php/archive/article/view/1174https://ir.kmu.edu.ua/handle/123456789/244Chronic Kidney Disease (CKD) is the steady loss of renal function over time. CKD can also constitute abnormalities in the kidney structure. Kidney damage is measured using albuminuria, structural abnormalities, electrolytes and other abnormalities, prior kidney transplant or a projected glomerular filtration rate (eGFR) <60 mL/min/1.73 m [1]. Even though CKD has no known cure, its advancement can be slowed down by regulating the risk factors like high blood glucose levels, high blood pressure and dyslipidemia [2]. According to Mohamed et al. [3] diabetes accounts for almost 44% of all new CKD cases; this means that approximately 1 in 3 patients with diabetes also have kidney disease. For this reason, this investigation was chosen to analyze the agents that can regulate blood glucose levels while having renoprotective effects that have been shown to be enormously beneficial in this patient group.enMEDICINE::Dermatology and venerology,clinical genetics, internal medicine::Internal medicine::Kidney diseasesdiabetesrenoprotectiveArticle